Wednesday, December 8, 2021
News

Novartis kicks off sale or hiving off Sandoz

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | Wednesday, 2021 4:15:06 AM IST
Novartis has launched a strategic review of the Sandoz division, the company said Tuesday. All options are on the table, including retaining the business and separation, Fierce Pharma reported.

A decision won't happen overnight; Novartis said it plans to offer an update on the review by the end of next year.

The company has previously tried to offload the under-pressure US oral solids business, together with a dermatology franchise, to India's Aurobindo Pharma for about $1 billion. But the two had to abandon the sale last Spring after hitting an antitrust review setback with the US Federal Trade Commission, the report said.

Sandoz has faced industrywide pressure on generics drug pricing, especially in the US, since around 2017. In the first nine months of 2021, Sandoz's sales in the US declined 17 per cent, while the whole unit's haul dropped 4 per cent year over year at constant currencies to $7.11 billion, the report said.

Novartis' solution for the franchise focuses on biosimilars and complex generics. Last month, Sandoz in-licensed a copycat referencing Roche's anti-VEGF drug Avastin from China's Bio-Thera Solutions. The firm is also in late-stage development of a biosimilar to Regeneron's top-selling VEGF inhibitor Eylea for eye diseases. But its launch of a biosim version of Amgen's TNF inhibitor Enbrel has been significantly delayed after legal defeats, the report said.

Sandoz plans to launch six biosimilar products across the US and EU in the next few years, and it has about 15 biosim programs internally or through partnerships, Sandoz CEO Richard Saynor told investors during a call Tuesday.

Novartis' goal is to make Sandoz a leading player in the generics market with stable sales growth at mid-single digit and profit margins around mid- to high-20 per cent. In the third quarter, Sandoz's profit margin reached 23.8 per cent, decreasing 3.4 percentage points.

As part of making Sandoz an autonomous unit within the group, Novartis has done some housekeeping work in the past few years. Sandoz's manufacturing operations have separated from the group's, Novartis CEO Vas Narasimhan told investors in April.

--IANS san/d

( 356 Words)

2021-10-26-22:16:03 (IANS)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Int'l passengers mandated to file self-d...
Enforce, follow Covid guidelines in Sada...
PMK demands detailed probe into 'fake' v...
NEET PG: Health Ministry asks SC to expe...
Wearing a mask could lower the risk by u...
Goa tracking down 'each and every aspect...
More...
 
INDIA WORLD ASIA
Nagaland to ask Centre to repeal AFSPA; ...
Want to bring back Mahatma Gandhi's Indi...
12-yr-old with rare liver disease underg...
81-yrs-old man in Hyderabad turns his ho...
406 elephants killed in Odisha during pa...
Dhankhar questions SEC's decision to hol...
More...    
 
 Top Stories
UAE govt announces four and half da... 
Telangana quite successful in attra... 
12-yr-old with rare liver disease u... 
US consular official to visit Afgha... 
Punjab CM pays surprise visit to Go... 
81-yrs-old man in Hyderabad turns h... 
Olaf Scholz to be sworn in as new G... 
406 elephants killed in Odisha duri...